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Abstract
Background: The gamma-aminobutyric acid (GABA) hypothesis in essential tremor (ET) implies a disturbance of the GABAergic system, especially involving the
cerebellum. This review examines the evidence of the GABA hypothesis.
Methods: The review is based on published data about GABA dysfunction in ET, taking into account studies on cerebrospinal fluid, pathology, electrophysiology,
genetics, neuroimaging, experimental animal models, and human drug therapies.
Results: Findings from several studies support the GABA hypothesis in ET. The hypothesis follows four steps: 1) cerebellar neurodegeneration with Purkinje cell
loss; 2) a decrease in GABA system activity in deep cerebellar neurons; 3) disinhibition in output deep cerebellar neurons with pacemaker activity; and 4) an increase
in rhythmic activity of the thalamus and thalamo-cortical circuit, contributing to the generation of tremor. Doubts have been cast on this hypothesis, however, by
the fact that it is based on relatively few works, controversial post-mortem findings, and negative genetic studies on the GABA system. Furthermore, GABAergic
drug efficacy is low and some GABAergic drugs do not have antitremoric efficacy.
Discussion: The GABA hypothesis continues to be the most robust pathophysiological hypothesis to explain ET. There is light in all GABA hypothesis steps, but a
number of shadows cannot be overlooked. We need more studies to clarify the neurodegenerative nature of the disease, to confirm the decrease of GABA activity in
the cerebellum, and to test more therapies that enhance the GABA transmission specifically in the cerebellum area.
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Introduction
Essential tremor (ET) is a common movement disorder in adults,
characterized by rhythmic shaking of the arms and possibly other parts
of the body. It is often referred to as a benign disorder but moderate
and advanced stages of ET can be physically and socially disabling.1
The few medications that have been used to treat ET have
demonstrated only modest efficacy.2
The etiology and pathophysiology of ET are not yet well under-
stood, thus limiting the rational development of new pharmacological
therapies for ET. There is some consensus about the involvement of
the cerebellum, but the exact neurochemical abnormalities underlying
the disorder remain to be identified.
The major pathophysiological hypothesis of ET during the last two
decades has been the GABA hypothesis.3 This hypothesis implies a
disturbance of the gamma-aminobutyric acid (GABA)ergic system in
ET, in particular involving the cerebellum. The hypothesis consists of
four main steps (Figure 1). Step 1 involves cerebellar degeneration with
Purkinje cell loss. In step 2, as a consequence of the previous step,
activity of the GABA system decreases in deep cerebellar neurons. In
step 3, pacemaker activity of deep cerebellar neurons is disinhibited.
And in step 4, the rhythmic activity of the thalamus and thalamo-
cortical circuit increases, causing tremor.
This review considers the evidence for and against the GABA
hypothesis with the objective of better understanding and defining the
pathophysiology of ET. Table 1 summarizes all the studies considered
herein concerning the GABA hypothesis in ET.
Cerebellum and GABA system
The cerebellum and the thalamus are the main regions involved in
the genesis (cerebellum) and propagation (thalamus) of tremor in
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humans. Clinical case studies have shown that lesions of these
structures can alleviate tremor.4,5 The ventral intermediate (VIM)
nucleus is the most effective target for stereotactic interventions to treat
tremor.6 Two studies using repetitive transcranial magnetic stimulation
applied over the cerebellum found a tremorlytic action in ET
patients.7,8 Furthermore, positron emission tomography (PET) activa-
tion studies show regional cerebral blood flow in the cerebellum is
abnormally increased.9–11 Magnetic resonance imaging (MRI) studies
including spectroscopy, voxel-based morphometry and functional
MRI also support cerebellar involvement in ET.12–14 Furthermore,
microscopic cerebellar pathology has been identified in these patients,
with cerebellar Purkinje cell loss with torpedoes and Bergmann
gliosis.15 In 2007, Louis and coworkers15 studied 33 ET brains and
found that about 75% of cases exhibited cerebellar pathology with a
loss of Purkinje cells and increased numbers of axonal torpedoes.
Further studies by the same group confirmed these findings.16–18
Cerebellar Purkinje cells are large neurons that have many branching
extensions. They are found in the cortex of the cerebellum and play a
fundamental role in controlling motor movement.19 These cells are
characterized by cell bodies that are flash-like in shape, the result of
numerous branching dendrites, and by a single long axon. Most Purkinje
cells release the neurotransmitter GABA, which exerts inhibitory actions on
the dentate nucleus and certain deep cerebellar output neurons, thereby
reducing the transmission of nerve impulses. These inhibitory functions
enable Purkinje cells to regulate and coordinate motor movements.
GABA is the major neurotransmitter for fast inhibitory synaptic
transmission.19 Because of its widespread presence and utilization, this
neurotransmitter is involved in all functions of the central nervous
system, including the cerebellum. In fact, the GABA system is the target
of a wide range of drugs that act on the central nervous system, such as
anxiolytics, sedative-hypnotics, general anesthetics, and anticonvulsants.
GABA is synthesized by a specific enzyme, L-glutamic acid
decarboxilase (GAD) in one step from L-glutamate. Thus, glutamate
must be available in certain nerve endings for biosynthesis of GABA.
Much of the glutamate and GABA used as a neurotransmitter is
derived from glial storage pools of glutamine. GABA is released from
electrically stimulated inhibitory nerve cells. The application of GABA
and structural analogues to cells innervated by GABAergic neurons
produces effects on that target cell identical to those produced by
stimulating the inhibitory innervation.
GABA binds to and mediates its effects via post-synaptic ionotropic
GABAA receptors and pre-and post-synaptic metabotropic GABAB
receptors.19,20 Whereas the GABAA receptors mediate fast responses,
the GABAB receptors mediate slow responses. GABA is removed from
the synaptic cleft by GABA transporters and metabolized. The GABAA
receptors are the main players in central nervous system (CNS) function
and relevance to psychopharmacology. These are the sites of action of
benzodiazepines, barbiturates, alcohol, general anesthetics, and neurosteroids.
Cerebrospinal fluid studies
In 1996, Mally et al.21 compared the concentrations of amino acids in the
cerebrospinal fluid (CSF) and serum in 20 patients with ET with those of a
control group of 10 subjects. They found a slight increase in the concentration
of glutamate and reduced levels of GABA, together with a decrease in glycine
and serine and a slight increase in the concentration of glutamate.
This work suggested a GABAergic dysfunction in ET and was one of
the first to provide evidence favoring the GABA hypothesis. Indeed,
the pathophysiological basis of ET seemed simple and would be the
result of a decrease in GABA, the main brain inhibitory neuro-
transmitter. However, this is the only study analyzing GABA levels in
CSF and the data have not been replicated.
Pathologic studies
A neuropathological study in 199620 revealed that GABAB receptors
are present on the presynaptic terminals of Purkinje cells in the deep
cerebellar nuclei. These anatomical structures have since been
considered involved in the probable genesis of ET.
A more recent neuropathological study on the GABA hypothesis in
ET found interesting results that agree with this hypothesis. In 2012
Paris-Robidas et al.22 reported a post-mortem decrease in GABAA (35%
reduction) and GABAB (22–31% reduction) receptors in the dentate
nucleus of the cerebellum in individuals with ET (n510) when
compared to controls (n516) or individuals with Parkinson’s disease
(n510), as assessed by receptor-binding autoradiography. Furthermore,
concentrations of GABAB receptors in the dentate nucleus were
inversely correlated with the duration of ET symptoms, suggesting that
the loss of GABAB receptors follows the progression of the disease. The
authors proposed that a decrease in GABA receptors in the dentate
nucleus disinhibits cerebellar pacemaker output activity, propagating
along the cerebello-thalamo-cortical pathways to generate tremors.
In the same year, Shill et al.23 studied some biochemical changes in
autopsied patients with ET comparing them with a control group. They
found significant reduced levels of parvalbumin (a marker of GABAergic
Figure 1. Schematic Representation of the Gamma-aminobutyric Acid
Hypothesis in Essential Tremor.
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Table 1. Studies Published Concerning the GABA Hypothesis in ET
CSF Purkinje Cell
Loss
Pathology GABA Electrophysiology Genetic Animal
Models
Imaging Drug Therapies
Pros Mally
et al.21
Louis et al.15 Mouginot and
Gahwiler20
Uusiaari and
Knopfel24
Kralic
et al.34
Boecket
et al.35
Theophylline,
199139
Axelrad et al.16 Paris-Robidas
et al.22
Pinault and
Deschenes28
Gironell
et al.36
Muscimol, 199140
Louis et al.18 Shill et al.23 Gabapentin, 199941
Gabapentin, 200043
Topiramate, 200245
Topiramate, 200646
Topiramate, 200848
Pregabaline, 200750
Cons Rajput et al.61 Deng et al.29 Progabide, 198337
Thier et al.30 Progabide, 198738
Shill et al.62 Garcı´a-Martı´n et al.31 Gabapentin, 199942
Symanski et al.63 Garcı´a-Martı´n et al.32 Topiramate, 200647
Tiagabine, 200849
Pregabaline, 200951
Pregabaline, 201252
CSF, Cerebrospinal Fluid; ET, Essential Tremor; GABA, gamma-aminobutyric acid.
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interneurons) in the pons and locus coeruleus with no difference in the
cerebellum. The results of the study partly agree with the GABA
hypothesis, suggesting a focal abnormality but not involving the
cerebellum.
Electrophysiological studies
Basic electrophysiology has provided valuable data for the GABA
hypothesis in ET. In 2008, Uusiaari and Knopfel24 demonstrated that
all dentate nucleus cells are sensitive to GABAergic input from
Purkinje cells. Using electrophysiological recordings of deep cerebellar
nuclei neurons they showed that both GABAA and GABAB receptors
mediate the inhibitory input coming from Purkinje cells.
Furthermore, several findings indicate that deep cerebellar nuclei
neurons belong to the family of single cell oscillators, and have a
pacemaker-like activity.20,25–28 Interestingly, in the case of deep
cerebellar nuclei neurons, it has been shown that their pacemaker-like
activity is under tonic control by the GABAergic input from Purkinje
cells.20 Even more compelling is the demonstration that deep
cerebellar nuclei neurons can impose their rhythmicity to their
thalamic target neurons with highly regular patterns of activity.28
Genetic studies
After several lines of evidence supported the GABA hypothesis, a
number of works in the last 10 years have analyzed the genetic bases of
this theory. The first approximation was negative. In 2006, Deng
et al.29 investigated the association between the GABAA receptor
alpha-1 and ET in 76 familial ET patients. The association did not
turn out to be significant. The authors concluded that missense,
nonsense, or splice site mutations in the coding regions of the GABAA1
gene are not a major genetic cause of ET.
More recent studies have been also negative. In 2011, Thier et al.30
investigated an association between polymorphisms in 15 GABAA and
four GABA transporter genes in ET. A total of 503 ET patients and
818 controls were analyzed. The authors did not find any evidence of
an association between GABAA and GABA transporter genes in ET.
Garcı´a-Martin et al.31 published two further negatives studies in
2011. In the first, they investigated the possible association between the
GABA receptor subtypes rho1, rho2, and rho3 and allelic variants of
the single nucleotide polymorphisms GABRR1-M26V, GABRR1-
H27R, GABRR2-T455M, and GABRR3-Y205X and the risk of ET.
The frequencies of GABBR1 genotypes and allelic variants of the
studied polymorphisms did not differ significantly between patients
with ET and controls and were unrelated to the age at onset of tremor,
gender, localization of tremor, and response of tremor to ethanol. In a
second work, the same authors studied the allelic and genotype
frequencies for single nucleotide polymorphisms, such as GABRA4-
L26M, GABRE-S102A, and GABRQ-I478F, in 200 patients with
familial ET and 250 healthy controls using TaqMan genotyping.32
Genotype and allelic frequencies did not differ significantly between
patients with ET and controls. The results of this study suggest that the
single nucleotide polymorphisms studied in the GABRA4, GABRE,
and GABRQ genes are not related to the risk for familial ET.
However, genetic studies in ET have several methodological
shortcomings: a lack of stringent diagnostic criteria, small sample
sizes, a lack of biomarkers, a high phenocopy rate, evidence of non-
mendelian inheritance, and high locus heterogeneity in presumably
monogenic ET.33
Experimental animal models
In 2005, Kralic et al.34 performed an interesting investigation using
GABA(A) receptor alpha-1 subunit knockout mice. This mouse model
exhibited postural and kinetic tremor and motor incoordination
characteristic of ET. The mice were tested using current ET drug
therapies such as primidone, propranolol, and gabapentin, and the
amplitude of the pathologic tremor decreased. Non-sedative doses of
ethanol eliminated tremor. No differences in abundance, gross
morphology, or spontaneous synaptic activity were observed in
cerebellar Purkinje cells. These cells exhibited a profound loss of all
responses to synaptic or exogenous GABA.
The authors concluded that this genetic animal model elucidates a
mechanism of GABAergic dysfunction in the major motor pathway
and potential targets for pharmacotherapy of ET.
In vivo imaging studies
[11C]Flumazenil is a tracer that specifically binds to the central
benzodiazepine receptor sites of the GABAA receptor complex. To
date, there are two main controlled PET studies using this tracer in
ET.
The first article was published in 2010.35 It was a comparative study
of [11C]flumazenil PET in eight patients with bilateral ET, with 11
healthy controls. Parametric distribution volume images were calculated
for focally altered [11C]flumazenil binding at the sites of tremor genesis,
in particular at the level of the cerebellum and interconnected thalamo-
cortical pathways. The authors found significant increases in binding of
[11C]flumazenil at the benzodiazepine receptor site of the GABAA
receptor in the cerebellum, the ventrolateral thalamus, and the lateral
premotor cortex in the ET group.
The second paper appeared in 2012.36 The authors performed
correlated clinical scale scores and parametric binding potential images
of [11C]flumazenil PET in 10 ET patients at different stages of clinical
severity. The severity of tremor statistically correlated with the
abnormalities found in GABA receptor binding in the cerebellar
vermis, bilateral posterior lobes, and right anterior lobe.
The results from both studies showed complete agreement with the
GABA hypothesis. Both studies provide neuroimaging evidence of
abnormally increased GABAA receptor binding in ET, especially in
cerebello-thalamic output pathways. In fact, the binding changes were
located in regions implicated in tremor genesis, such as the thalamus,
the cerebellum, and the lateral premotor cortex. We can conclude
from these findings that in vivo neuroimaging studies support the role of
cerebellar GABAergic dysfunction as the main pathophysiological
hypothesis of the disease.
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Human drug therapies
One of the major premises of the GABA hypothesis in ET was the
antitremoric effects observed in some GABAergic drugs, such as
gabapentin, in the late 1990s.
Progabide. The first controlled trial of a GABA-agonist, progabide, in
ET was performed in 1983. Mondrup et al.37 performed a study in
18 ET patients. They found no significant differences between
progabide and placebo in tremor scores.
Four years later, Koller et al.38 performed another controlled trial
with progabide in 10 ET patients. Again, there were no differences on
tremor scores from placebo. The authors concluded that alterations in
GABA neurotransmission do not appear to be involved in the
pathogenesis of ET.
Theophylline. In 1991, Mally et al.39 studied the effects of theophylline
in 20 ET patients in a double-blind crossover trial. Tremor improved
significantly after 4 weeks of treatment. The authors hypothesized that
theophylline-enhanced GABA explains the antitremoric effect.
Muscimol. In 1999, Pahapill et al.40 performed an interesting
experiment injecting muscimol (GABAA agonist) into the ventralis
intermedius thalamus in six patients undergoing stereotactic procedures
for ET. The drug was administered in areas where tremor-synchronous
cells were identified electrophysiologically with microelectrode record-
ings and where tremor reduction occurred with electrical microstimula-
tion. Injections of muscimol but not saline solution consistently reduced
tremor in each patient. The authors concluded that GABA-mediated
thalamic neuronal inhibition may represent a mechanism underlying
the effectiveness of surgery for tremor and that GABA analogues could
potentially be used therapeutically.
Gabapentin. Gabapentin is structurally related to the neurotransmitter
GABA. It penetrates the blood–brain barrier but it does not modify
GABAA or GABAB radioligand binding, it is not converted
metabolically into GABA or a GABA agonist, and it is not an
inhibitor of GABA uptake or degradation. Its mechanism of action is
not fully understood, but recent data indicate that it can increase
human brain GABA levels and reduce intracortical excitability.
In 1999, Gironell et al.41 performed a randomized placebo-
controlled comparative trial of gabapentin and propranolol in 16 ET
patients. The patients were not taking antitremoric medication. On
day 15, both gabapentin and propranolol demonstrated significant and
comparable efficacy in reducing tremor from baseline in all tremor
measures (clinic and accelerometric). Results of the study were in
accordance with the central mechanism hypothesis that implicates the
GABAergic system in the pathogenesis of ET. The authors concluded
that their exploratory study suggested gabapentin deserved a role in
the pharmacological treatment of ET.
In the same year, Pahwa et al.42 performed another controlled study
of gabapentin in ET in 20 ET patients. Although some patient had
benefits on tremor, the results were not statistically significant for total
tremor scores.
One year later, Ondo et al.43 performed a multiple-dose, double-
blind, placebo-controlled trial with gabapentin in 25 ET patients.
Some end points of the study were positive (patient global assessment,
water-pouring scores, observed tremor scores, and activities of daily
living). However, accelerometry, spirographs, and investigator global
impressions scores did not improve. The results were similar for high
and low doses. The authors concluded that gabapentin may be
effective in some cases of ET.
In the American Academy of Neurology (AAN) recent guidelines for
ET, gabapentin appeared with a type B level of evidence.44
Topiramate. Topiramate is an anticonvulsant that blocks sodium
channels and potentiates GABA activity. Following the GABA
hypothesis in ET, several trials were done using this drug for ET. In
2002, Connor45 found significant antitremoric properties of topir-
amate in a controlled study in 24 ET patients. Topiramate improved
all tremor clinical scores. In a multicenter-controlled study, Ondo
et al.,46 revealed significant improvement in tremor in 208 ET patients.
The mean percentage improvement in overall scores was 29%. In 2006,
Frima and Gru¨newald,47 performed a controlled crossover study of
topiramate in 16 ET patients. The study was negative, and provided no
evidence of therapeutic benefit of topiramate in ET. And in 2008,
Connor et al.48 performed a double-blind placebo controlled crossover
study of topiramate in ET with 62 patients. The authors found a
significant improvement (18–23%) in all tremor measures following
treatment with topiramate. However, the drop-out rate was approxi-
mately 40% due to appetite suppression, weight loss, paresthesias,
anorexia, and concentration difficulties.
Tremor efficacy of topiramate is similar to gabapentin, but titration
is long and difficult, and tolerance is poor. In recent AAN guides for
ET treatment, topiramate is considered a second-line therapy with a
level of evidence B.44
Tiagabine. Tiagabine is a centrally acting GABA uptake inhibitor that
allows more GABA to be available for post-synaptic receptor binding.
Following the GABA hypothesis in ET, tiagabine may have
antitremoric properties in ET patients.
Gironell et al.49 performed an open-label trial with seven ET
patients. Results were negative, and at the dosage tested they did not
lead to a significant improvement in tremor amplitudes in ET.
Pregabaline. Pregabaline is a structural derivative of the inhibitory
neurotransmitter GABA. In a similar way to gabapentin, it does not
bind directly to GABAA, GABAB, or benzodiazepine receptors, does
not increase GABA responses in cultured neurons, and does not alter
rat brain GABA concentration or have acute effects on GABA uptake
or degradation. However, in cultured neurons, prolonged application
of pregabaline increases the density of GABA transporter protein and
increases the rate of functional GABA transport.
In 2007, Zesievick et al.50 first published a double blind study of
pregabaline in 22 ET patients. The authors found significant
improvement in accelerometry and tremor clinical scores. However,
2 years later, Ferrara et al.51 performed another controlled study with
GABA Hypothesis in Essential Tremor Gironell A
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pregabalin in 20 ET patients with a titration period of 6 weeks and
found no improvement in any of the tremor measures.
Finally, in a multisite, double-blind study in 2012, Zesievick et al.52
published a study of pregabalin in 29 ET patients. The study was
negative, and there were no improvements in any tremor measures.
Other drugs that enhance GABAergic transmission. Several classes of
drugs that enhance GABAergic transmission by binding to sites on the
GABAA receptors are effective in the treatment of ET. These include
barbiturates (fenobarbital, primidone), and benzodiazepines (alprazo-
lam and clonacepam). Primidone is a first-class antitremoric agent that
has a similar efficacy to beta-blockers (level of evidence AAN: B).53,54
Alprazolam is probably efficacious in treating ET (level of evidence
AAN: C).55
Ethanol, which is often highly effective in reducing the severity of
tremor in ET, potentiates the activity of the GABAA receptor.
56
Alcohol, in fact, is an indirect GABA agonist. It is believed to mimic
GABA’s effect on the brain, binding to GABA receptors and inhibiting
neuronal signaling.
While propranolol is believed to have a therapeutic effect on ET by
antagonistic binding to non-specific peripheral beta-adrenergic
receptors, there is some evidence to suggest that it may also act by
enhancing GABA receptivity in the central nervous system.57
GABA hypothesis in ET: light
N Step 1: cerebellar neurodegeneration with cerebellar Purkinje cell
loss.
Some pathological post-mortem studies agree with the GABA
hypothesis, revealing Purkinje cell loss in ET.15–18 Furthermore, the
neurodegenerative nature of ET is supported by the progressive course
of the disease.58
N Step 2: decrease in GABA system activity in deep cerebellar
neurons
Several studies agree with this hypothesis:
- CSF studies demonstrating a decrease in GABA levels.21
- Pathological studies that found a decrease in GABA receptors
in the dentate nucleus.22
- In vivo imaging studies, with an increase of binding of
flumazenil in GABA receptors in the cerebellar area, thus,
suggesting a deficit in GABA in these areas.35,36
- Animal model (knockout mice) of GABA dysfunction exhibit
symptoms characteristic of ET.34
- -Antitremoric efficacy of drugs that enhance GABA activity
including, muscimol, theophylline, gabapentin, topiramate,
tiagabine, pregabaline, primidone, benzodiazepines and
alcohol.39,40,41,43,45,46,48,50,53–57
N Step 3: disinhibition in output deep cerebellar neurons with
pacemaker activity.
- Electrophysiological studies indicating that dentate nucleus
cells are sensitive to GABAergic input from Purkinje cells, and
that deep cerebellar nuclei neurons have pacemaker-like
activity.20,24–28
- Evidence of this step is the increase in output cerebellar metabolism
that appears in PET studies with 18Fludeoxyglucose (FDG).9–11
- The antitremoric effect of inhibitory repetitive transcranial
magnetic stimulation (rTMS) over the cerebellum also
supports an increase in hypermetbolism and activity in this
area.7,8
N Step 4: Increase in rhythmic activity of thalamus and thalamo-
cortical circuit.
Thalamic rhythmic or tremoric neurons, specifically in VIM
nucleus, have been clearly seen in electrophysiological recordings in
deep brain stimulation surgery.59,60
GABA hypothesis in ET: lights and shadows
There are a number of arguments against the GABA hypothesis in
ET. The main one is that evidence of a decrease in cerebellar GABA
activity is based on relatively few studies. Only one study has found a
decrease in GABA in CSF and only one neuropathological study has
revealed a decrease in GABA receptors. Besides, only two controlled
studies have analyzed in vivo imaging data.
There are several other important shadows hanging over the GABA
hypothesis. The neuropathology of ET, in particular cerebellar
pathology, is a matter of controversy. Several post-mortem studies
have not revealed Purkinje cell loss in ET.61–63 However, the Rajput
et al.61 study was underpowered to detect Purkinje cell loss, and the
Shill et al.62 study is problematic for reasons of case definition. Based
on these negative studies, some authors consider ET may not be a
neurodegenerative disease, and point to an abnormal neuronal
oscillation as the fundamental abnormality in this disorder.64,65 The
controversial results of the various neuropathologic studies in ET are
difficult to explain and may be related to three possibilities: 1) patient
selection biases; 2) different methodologies and counting methods; and
3) differences in field sizes and lack of standardization across studies,
restricting microscopy to linear segments.66 These biases have to be
controlled in further standardized studies.
Moreover, all genetic studies involving several nucleotide GABA
polymorphisms and GABAA receptor and GABA transporter genes
have been negative.29–32
Also of concern is the therapeutic failure of several GABAergic
drugs in controlled studies. These include progabide, gabapentin,
topiramate, tiagabine, and pregabaline.37,38,42,47,49,51,52 Furthermore,
efficacy of GABAergic drugs with antitremoric properties is relatively
scarce, with maximum improvements of about 30–60%.2
However, simply enhancing GABA neurotransmission may be too
gross a solution to the problem. Loss of GABA in ET may be a
marker of the problem (Purkinje cell loss) but the problem produced
by Purkinje cell loss may not simply be fixed by enhancing GABA
transmission.
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Final remarks
To sum up and conclude, we can state that the GABA hypothesis
remains the most robust pathophysiological theory of ET to date.
There is light in all the steps of the GABA hypothesis. However, the
evident shadows and controversies cannot be overlooked. We clearly
need to perform more studies to confirm the neurodegenerative nature
of the disease and more studies about the decrease in GABA activity in
the cerebellum, and we need to test more therapies that enhance
GABA transmission specifically focused in the cerebellum area.
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